Linked Life Data

20084425

Source:http://linkedlifedata.com/resource/pubmed/id/20084425

Statements in which the resource exists as a subject.
PredicateObject
rdf:type
lifeskim:mentions
pubmed:issue
2
pubmed:dateCreated
2011-2-11
pubmed:abstractText
2-methoxyestradiol (2ME2) is an estradiol-17? metabolite with antiproliferative and antiangiogenic activities. ENMD-1198 is an analog of 2ME2 which was developed to decrease the metabolism and increase both the bioavailability and antitumor activities of the parent molecule. This first-in-human phase I study evaluated the tolerability, pharmacokinetics and preliminary evidence of activity of ENMD-1198 in advanced cancer patients.
pubmed:language
eng
pubmed:journal
pubmed:citationSubset
IM
pubmed:chemical
pubmed:status
MEDLINE
pubmed:month
Apr
pubmed:issn
1573-0646
pubmed:author
pubmed:issnType
Electronic
pubmed:volume
29
pubmed:owner
NLM
pubmed:authorsComplete
Y
pubmed:pagination
340-6
pubmed:meshHeading
pubmed:year
2011
pubmed:articleTitle
A phase I dose-escalation, safety and pharmacokinetic study of the 2-methoxyestradiol analog ENMD-1198 administered orally to patients with advanced cancer.
pubmed:affiliation
Developmental Therapeutics Program, Division of Medical Oncology, University of Colorado, Aurora, CO 80045, USA.
pubmed:publicationType
Journal Article, Clinical Trial, Phase I